SGLT2 Inhibitor Use in Stage 5 CKD Cuts Risks for Cardiovascular, Kidney Events

This study is among the first to report outcomes of sodium-glucose cotransporter-2 (SGLT2) inhibitor therapy in stage 5 chronic kidney disease (CKD).

Related Keywords

Taiwan ,Miaoli County ,Miaoli Xian ,China ,Chinese ,Chih Cheng Hsu ,National Health Research Institutes In Miaoli ,Taiwan National Health Insurance Research Database ,National Health Insurance Research Database ,National Health Research Institutes ,Both Kaplan Meier ,